 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||
4 May 2004 | Volume 140 Issue 9 | Pages 709-713
Background: Tuberculosis control hinges on prompt diagnosis of active cases and screening of contacts by tuberculin skin testing. Rapid blood tests for Mycobacterium tuberculosis infection are a new alternative to the tuberculin skin test, but whether they improve clinical outcomes is unknown.
Objective: To describe how a novel T-cell–based test for M. tuberculosis infection helped diagnose tuberculosis in an asymptomatic, immunosuppressed adult with a negative result on a tuberculin skin test.
Design: Case report.
Setting: Household contact.
Patients: Asymptomatic man receiving maintenance azathioprine therapy for Crohn disease whose wife had multidrug-resistant pulmonary tuberculosis.
Measurements: Enzyme-linked immunospot (ELISPOT) assay, computed tomography, and bronchoalveolar lavage cultures.
Results: The man had a negative tuberculin skin test result and a positive ELISPOT assay result. High-resolution computed tomography of the chest showed consolidation with early cavitation. Bronchoalveolar lavage and culture confirmed multidrug-resistant tuberculosis.
Limitations: This single case report is a proof of concept and is not a formal evaluation of clinical utility.
Conclusions: A positive ELISPOT assay result helped diagnose subclinical active tuberculosis in an immunosuppressed patient with a false-negative tuberculin skin test result. Large prospective studies that compare benefits and costs of this alternative to tuberculin skin testing are needed.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From University of Modena and Reggio Emilia and Azienda Ospedaliera Policlinico di Modena, Modena, Italy; University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; and Royal Brompton Hospital, London, United Kingdom.
Acknowledgments: The authors thank Patrizia Marchegiano (Azienda Ospedaliera Policlinico di Modena, Modena, Italy) for helping with the organization of the study and Giulio Ferrario and Andrea Gori (University of Milano, Milan, Italy) for restriction fragment length polymorphism typing. The authors also thank Peter Barnes (Center for Pulmonary and Infectious Disease Control, Tyler, Texas), Anna M. Marata (CeVEAS, Modena, Italy), and Giovanni B. Migliori (Tradate, Italy) for their helpful comments.
Grant Support: By the Wellcome Trust (London, United Kingdom) and the Azienda Ospedaliera Policlinico di Modena (Modena, Italy). Ajit Lalvani is a Wellcome Senior Research Fellow in clinical science.
Potential Financial Conflicts of Interest:Consultancies: A. Lalvani (Oxford Immunotec Ltd.); Stock ownership or options (other than mutual funds): A. Lalvani (Oxford Immunotec Ltd.); Patents received, patents pending, and royalties: A. Lalvani (patents filed by the University of Oxford since 1996 relating to T-cell–based diagnosis); Patents pending: K. Ewer (named as inventor on a patent application relating to the application of the RD-1–based ELISPOT assay); Other: The University of Oxford owns stock in Oxford Immunotec Ltd.
Requests for Single Reprints: Ajit Lalvani, MRCP, DM, Nuffield Department of Clinical Medicine, University of Oxford, Level 7, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom; e-mail, ajit.lalvani{at}ndm.ox.ac.uk.
Current Author Addresses: Drs. Richeldi, Roversi, and Fabbri and Ms. Losi: Policlinico di Modena, via del Pozzo 71, 41100 Modena, Italy.
Ms. Ewer and Dr. Lalvani: John Radcliffe Hospital, Level 7, Oxford OX3 9DU, United Kingdom.
Dr. Hansell: Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom.
Author Contributions: Conception and design: L. Richeldi, K. Ewer, A. Lalvani.
Analysis and interpretation of the data: L. Richeldi, K. Ewer, M. Losi, D.M. Hansell, A. Lalvani.
Drafting of the article: L. Richeldi, K. Ewer, A. Lalvani.
Critical revision of the article for important intellectual content: L. Richeldi, K. Ewer, D.M. Hansell, M. Losi, A. Lalvani.
Final approval of the article: L. Richeldi, K. Ewer, M. Losi, D.M. Hansell, P. Roversi, L.M. Fabbri, A. Lalvani.
Provision of study materials or patients: A. Lalvani.
Statistical expertise: K. Ewer.
Obtaining of funding: L.M. Fabbri, A. Lalvani.
Administrative, technical, or logistic support: M. Losi, P. Roversi, L.M. Fabbri, A. Lalvani.
Collection and assembly of data: L. Richeldi, K. Ewer, M. Losi, D.M. Hansell, P. Roversi, A. Lalvani. BRIEF COMMUNICATION
Early Diagnosis of Subclinical Multidrug-Resistant Tuberculosis
This article has been cited by other articles:
|
|
 |
|
  A. Strassburg, C. Jafari, M. Ernst, W. Lotz, and C. Lange Rapid diagnosis of pulmonary TB by BAL enzyme-linked immunospot assay in an immunocompromised host Eur. Respir. J., May 1, 2008; 31(5): 1132 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dominguez, J. Ruiz-Manzano, M. De Souza-Galvao, I. Latorre, C. Mila, S. Blanco, M. A. Jimenez, C. Prat, A. Lacoma, N. Altet, et al. Comparison of Two Commercially Available Gamma Interferon Blood Tests for Immunodiagnosis of Tuberculosis Clin. Vaccine Immunol., January 1, 2008; 15(1): 168 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Losi, A. Bossink, L. Codecasa, C. Jafari, M. Ernst, S. Thijsen, D. Cirillo, M. Ferrarese, U. Greinert, L. M. Fabbri, et al. Use of a T-cell interferon-{gamma} release assay for the diagnosis of tuberculous pleurisy Eur. Respir. J., December 1, 2007; 30(6): 1173 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sellam, H. Hamdi, C. Roy, G. Baron, M. Lemann, X. Puechal, M. Breban, F. Berenbaum, M. Humbert, K. Weldingh, et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy Ann Rheum Dis, December 1, 2007; 66(12): 1610 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. A. Kang, H. W. Lee, S. S. Hwang, S.-W. Um, S. K. Han, Y.-S. Shim, and J.-J. Yim Usefulness of Whole-Blood Interferon-{gamma} Assay and Interferon-{gamma} Enzyme-Linked Immunospot Assay in the Diagnosis of Active Pulmonary Tuberculosis Chest, September 1, 2007; 132(3): 959 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. van Leeuwen, A. W. J. Bossink, and S. F. T. Thijsen From the authors Eur. Respir. J., July 1, 2007; 30(1): 184 - 185. [Full Text] [PDF]
|
|
|
|
|
|
E. Porsa, L. Cheng, and E. A. Graviss Comparison of an ESAT-6/CFP-10 Peptide-Based Enzyme-Linked Immunospot Assay to a Tuberculin Skin Test for Screening of a Population at Moderate Risk of Contracting Tuberculosis Clin. Vaccine Immunol., June 1, 2007; 14(6): 714 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Menzies, M. Pai, and G. Comstock Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research Ann Intern Med, March 6, 2007; 146(5): 340 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Richeldi, K. Ewer, M. Losi, B. M. Bergamini, K. Millington, L. M. Fabbri, and A. Lalvani T-Cell-Based Diagnosis of Neonatal Multidrug-Resistant Latent Tuberculosis Infection Pediatrics, January 1, 2007; 119(1): e1 - e5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Sester, H. Junker, T. Hodapp, A. Schutz, B. Thiele, A. Meyerhans, H. Kohler, and M. Sester Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3258 - 3268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Richeldi An Update on the Diagnosis of Tuberculosis Infection Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 736 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Piana, L. R. Codecasa, P. Cavallerio, M. Ferrarese, G. B. Migliori, L. Barbarano, E. Morra, and D. M. Cirillo Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients Eur. Respir. J., July 1, 2006; 28(1): 31 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wrighton-Smith and J-P. Zellweger Direct costs of three models for the screening of latent tuberculosis infection Eur. Respir. J., July 1, 2006; 28(1): 45 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Richeldi, G. Ferrara, M. Losi, R. Piro, P. Roversi, and L. M. Fabbri Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 130a - 131. [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrara, M. Losi, M. Meacci, B. Meccugni, R. Piro, P. Roversi, B. M. Bergamini, R. D'Amico, P. Marchegiano, F. Rumpianesi, et al. Routine Hospital Use of a New Commercial Whole Blood Interferon-{gamma} Assay for the Diagnosis of Tuberculosis Infection Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 631 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Richeldi, K. Ewer, M. Losi, B. M. Bergamini, P. Roversi, J. Deeks, L. M. Fabbri, and A. Lalvani T Cell-Based Tracking of Multidrug Resistant Tuberculosis Infection after Brief Exposure Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 288 - 295. [Abstract] [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
